PET/MRI在激素分泌性垂体微腺瘤诊断中的应用:一项前瞻性先导研究
该前瞻性先导研究纳入37例激素水平升高患者(19例原发性垂体腺瘤无法确诊、18例疑似复发性垂体腺瘤),行18F-FDG与68Ga-DOTATATE PET/MRI,并与手术病理及临床随访对照。结果显示腺瘤18F-FDG摄取高于正常垂体组织,68Ga-DOTATATE摄取低于正常垂体组织,18F-FDG/68Ga-DOTATATE SUVmax比值鉴别腺瘤与正常垂体的诊断效能最佳。
要点
- 腺瘤18F-FDG SUVmax高于正常垂体组织,68Ga-DOTATATE SUVmax低于正常垂体组织。
- 18F-FDG/68Ga-DOTATATE SUVmax比值鉴别腺瘤与正常垂体的诊断效能最佳,最佳 cutoff 为1.04。
- 单独18F-FDG SUVmax的最佳诊断 cutoff 为3.88,诊断效能略低于比值。
核心结论
- PET/MRI为激素分泌性垂体微腺瘤的检测提供了理想工具。
- 双示踪剂18F-FDG与68Ga-DOTATATE PET/MRI有助于区分垂体微腺瘤与正常垂体组织。
研究设计与样本
- 前瞻性先导研究,招募37例激素水平升高患者,其中19例原发性垂体腺瘤无法确诊、18例疑似复发性垂体腺瘤。
- 所有患者均在同1周内完成18F-FDG PET/MRI与68Ga-DOTATATE PET/MRI检查。
- 37例中27例行经蝶窦腺瘤切除术,3例行鞍区放疗,1例行生长抑素治疗,6例仅临床随访。
- 图像特征与摄取水平同手术所见及病理结果进行相关性分析,并用受试者工作特征曲线确定鉴别腺瘤与正常垂体组织的最佳 cutoff。
主要发现
- 所有患者中均清晰观察到18F-FDG摄取增高,PET/MR图像具有诊断质量且无明显伪影。
- MRI增强扫描(钆喷酸葡胺0.05 mmol/kg剂量)在原发性腺瘤患者中仅47%显示提示性发现,在复发性腺瘤患者中为39%;使用0.1 mmol/kg剂量时,相应比例分别为37%和50%。
- 16例经蝶窦腺瘤切除术的原发性腺瘤18F-FDG SUVmax为6.8 ± 3.7,显著高于正常垂体组织的3.2 ± 1.1(P < 0.01)。
- 腺瘤68Ga-DOTATATE摄取为中等(SUVmax 3.8 ± 2.6),但一般低于正常垂体组织的SUVmax 6.2 ± 3.2(P < 0.05)。
- 11例经蝶窦腺瘤切除术的疑似复发性腺瘤18F-FDG SUVmax为6.1 ± 3.5,显著高于正常垂体组织的2.5 ± 1.1(P < 0.01);68Ga-DOTATATE SUVmax为3.0 ± 1.1,显著低于正常垂体组织的5.5 ± 1.7(P < 0.01)。
关键数值与推荐
- 18F-FDG/68Ga-DOTATATE SUVmax比值鉴别腺瘤与正常垂体组织的最佳诊断 cutoff 为1.04。
- 单独18F-FDG SUVmax鉴别腺瘤与正常垂体组织的最佳诊断 cutoff 为3.88。
- MRI增强使用钆喷酸葡胺0.05 mmol/kg剂量时,原发性腺瘤患者提示性发现比例为47%,复发性腺瘤患者为39%;使用0.1 mmol/kg剂量时分别为37%和50%。
临床怎么用
- 原文结论认为PET/MRI为激素分泌性垂体微腺瘤的检测提供了理想工具。
- 原文结论认为双示踪剂18F-FDG与68Ga-DOTATATE PET/MRI有助于区分垂体微腺瘤与正常垂体组织。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study was designed to evaluate the ability of PET/MRI, using 18F-FDG and 68Ga-DOTATATE as tracers, to detect hormone-producing pituitary microadenoma when diagnosis is difficult using MRI alone. Methods: We recruited 37 patients with elevated hormone levels, including 19 with undiagnosable primary pituitary adenoma and 18 with suspected recurrent pituitary adenoma. 18F-FDG PET/MRI and 68Ga-DOTATATE PET/MRI were performed within 1 wk of each other in all patients. Within 2 wk afterward, 27 of the 37 patients underwent transsphenoidal adenomectomy, 3 underwent sella region radiotherapy, 1 underwent somatostatin therapy, and 6 had only clinical follow-up. The image characteristics and uptake levels were correlated with the surgical findings and pathologic results. Receiver-operating-characteristic curves were analyzed to determine the optimal cutoff to differentiate adenoma from normal pituitary tissue. The area under the receiver-operating-characteristic curve was calculated to compare diagnostic performance. Results: The PET/MR images were of diagnostic quality and without obvious image artifacts. The high contrast of the PET images provided complementary information to the fine anatomic display of the MR images. Increased 18F-FDG uptake was clearly observed in all patients. MRI enhanced using a 0.05 mmol/kg dose of gadopentetate dimeglumine showed suggestive findings in only 47% of the patients with primary adenoma and 39% of those with recurrent adenoma; when a 0.1 mmol/kg dose was used, the respective percentages were 37% and 50%. The 18F-FDG SUVmax of the 16 primary adenomas that underwent transsphenoidal adenomectomy (6.8 ± 3.7) was significantly higher than that of normal pituitary tissue (3.2 ± 1.1, P < 0.01). The adenomas showed moderate 68Ga-DOTATATE uptake (SUVmax, 3.8 ± 2.6), but the 68Ga-DOTATATE uptake was generally lower than that of normal pituitary tissue (SUVmax, 6.2 ± 3.2, P < 0.05). In the 11 suspected recurrent pituitary adenomas that underwent transsphenoidal adenomectomy, the 18F-FDG SUVmax was 6.1 ± 3.5, significantly higher than that of normal pituitary tissue (2.5 ± 1.1, P < 0.01), and the 68Ga-DOTATATE SUVmax was 3.0 ± 1.1, significantly lower than that of normal pituitary tissue (5.5 ± 1.7, P < 0.01). The 18F-FDG/68Ga-DOTATATE SUVmax ratio of the adenomas (2.3 ± 1.5) was significantly higher than that of normal pituitary tissue (0.6 ± 0.3, P < 0.05). When the 18F-FDG SUVmax alone and the 18F-FDG/68Ga-DOTATATE SUVmax ratio were used as criteria to discriminate between adenoma and pituitary tissue, the best analysis came from the ratio, and that from 18F-FDG SUVmax alone was slightly less, with optimal diagnostic cutoffs of 1.04 and 3.88, respectively. Conclusion: PET/MRI provides an ideal tool for the detection of hormone-producing pituitary microadenoma. Dual-tracer 18F-FDG and 68Ga-DOTATATE PET/MRI was useful for distinguishing pituitary microadenoma from normal pituitary tissue.
引用
- Wang H, Hou B, Lu L, et al. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study. J Nucl Med. 2017. PMID: 28775202. doi:10.2967/jnumed.117.191916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。